DEGRADED ANTIBODY AS TPO AGONIST Russian patent published in 2006 - IPC C07K16/18 A61K39/395 G01N33/53 A61P7/00 

FIELD: biotechnology, medicine, immunology.

SUBSTANCE: invention relates to a modified antibody comprising two or more V-regions in H-chain and two or more V-regions in L-chain of antibody bound directly or over a linker by covalent or noncovalent bond. Antibody has a lesser size as compared with the parent antibody possessing or not possessing the agonistic effect to TPO receptors. Antibody represents TPO agonist and able for specific recognizing and cross-linking the TPO receptor. For induction of the agonistic effect in cells expressing TPO receptors cells are contacted with the modified antibody. Measurement of the antibody TRO-agonistic effect is carried out by cross-linking TRO receptors. The modified antibody can be used as a medicinal agent in treatment of thrombocytopenia. Modified antibodies possess higher activity as compared whole antibodies (JgG) and improved penetration capacity into tissues owing to decreased molecular sizes and absence of constant regions.

EFFECT: improved and valuable properties of antibody.

38 cl, 92 dwg, 3 tbl, 8 ex